alt Hacker NewsOzempic is just scratching the surface, the pipeline is bursting...
>...combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA.
I count 18 or so here...
Thanks for sharing that link. Retatrutide looks especially promising since it targets three different receptors (GLP-1, GIP, and glucagon) instead of just GLP-1 like Ozempic. This triple action appears to have a more comprehensive effect on metabolism. So it may increase energy expenditure in addition to reducing calorie intake. This drug also showed significant improvements in lipid profiles, blood pressure, and liver fat reduction. If all goes well we should expect to have it in 3-4 years.